AU2015208819B2 - Compositions and methods for treating intracerebral hemorrhage - Google Patents

Compositions and methods for treating intracerebral hemorrhage Download PDF

Info

Publication number
AU2015208819B2
AU2015208819B2 AU2015208819A AU2015208819A AU2015208819B2 AU 2015208819 B2 AU2015208819 B2 AU 2015208819B2 AU 2015208819 A AU2015208819 A AU 2015208819A AU 2015208819 A AU2015208819 A AU 2015208819A AU 2015208819 B2 AU2015208819 B2 AU 2015208819B2
Authority
AU
Australia
Prior art keywords
ich
less
fxa
subject
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015208819A
Other languages
English (en)
Other versions
AU2015208819A1 (en
Inventor
Steven ARKIN
Marcus E. Carr
Joachim Fruebis
Sunita HETT
Reema JASUJA
Debra D. Pittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2015208819A1 publication Critical patent/AU2015208819A1/en
Application granted granted Critical
Publication of AU2015208819B2 publication Critical patent/AU2015208819B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015208819A 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage Ceased AU2015208819B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
AU2015208819A1 AU2015208819A1 (en) 2016-06-30
AU2015208819B2 true AU2015208819B2 (en) 2020-01-23

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015208819A Ceased AU2015208819B2 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20160093731A (enExample)
CN (2) CN105934250A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
KR20260076240A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs5117 마커 조성물 및 이의 용도
KR20260076239A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs429358 마커 조성물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059513A2 (en) * 2005-11-15 2007-05-24 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06015045A (es) * 2004-06-21 2007-03-21 Novo Nordisk Healthcare Ag Uso del factor viia o equivalentes del factor viia para prevenir o atenuar el crecimiento de hemorragias y/o generacion de edemas despues de una hemorragia intracerebral.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EP2467166A2 (en) * 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
KR102049900B1 (ko) * 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059513A2 (en) * 2005-11-15 2007-05-24 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Also Published As

Publication number Publication date
DK3096779T3 (da) 2020-02-24
BR112016014617A2 (pt) 2017-09-19
JP6624787B2 (ja) 2019-12-25
MX375355B (es) 2025-03-04
SI3096779T1 (sl) 2020-03-31
CN105934250A (zh) 2016-09-07
HUE047588T2 (hu) 2020-04-28
AU2015208819A1 (en) 2016-06-30
PT3096779T (pt) 2020-02-21
WO2015110939A1 (en) 2015-07-30
EP3096779B1 (en) 2019-12-18
US20160375109A1 (en) 2016-12-29
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
US20190231856A1 (en) 2019-08-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
IL246637A0 (en) 2016-08-31
RU2016126423A3 (enExample) 2018-03-01
EP3096779A1 (en) 2016-11-30
ES2772802T3 (es) 2020-07-08
KR20180014221A (ko) 2018-02-07
CN112156176A (zh) 2021-01-01
KR20160093731A (ko) 2016-08-08
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
RU2016126423A (ru) 2018-03-01

Similar Documents

Publication Publication Date Title
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
CN101505785A (zh) 替奈普酶用于治疗急性缺血性中风的用途
JP6514893B2 (ja) 止血を調節するための組成物および方法
JP2016511755A (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
JP2022547050A (ja) 治療用融合タンパク質
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
EP3420087B1 (en) Peptide-based methods for treating neurological injury
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
KR20250084963A (ko) 연조직에 투여하기 위한 인자 ix 변이체 폴리펩타이드
WO2023147574A2 (en) Compositions and methods for treating factor ix deficiency
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
US20250302927A1 (en) Modified factor xa polypeptides and methods of use
WO2010078469A2 (en) Sand fly salivary proteins as novel factor xa inhibitors and methods of use
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
JP2006180840A (ja) 血栓の溶解を亢進させるポリペプチド及びその利用
HK1196289B (en) Medicine for treatment and/or improvement of sepsis
JP2006180841A (ja) 血栓の溶解を抑制させるポリペプチド及びその利用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired